feb 13, 2018: 9 a.m. - 9:55 a.m.
With official recognition of the magnitude of the opioid abuse crisis, government institutions and investors are showing increased willingness to support novel approaches to attacking this health challenge. This session will explore the most promising avenues in the neuroscience of addiction and alternatives to opioid-based pain management, as well as identify the most pressing bottlenecks in our understanding of the brain’s addiction to painkillers.
Data Introduction: David Thomas, CFA, Senior Director, Industry Research & Analysis, Biotechnology Innovation Organization
Moderator: Michael Detke, MD, PhD, Chief Medical Officer, Embera NeuroTherapeutics, Inc.
Roger Crystal, MD, Chief Executive Officer, Opiant
Brandon Folkes, Director, Specialty Pharmaceuticals Analyst, Cantor Fitzgerald
Lucy Lu, MD, President and CEO, Avenue Therapeutics
Corey McCann, MD, PhD, Founder and Chief Executive Officer, Pear Therapeutics
Robert Radie, President and Chief Executive Officer, Egalet Corporation
Peter Strumph, President and Chief Executive Officer, Amygdala Neurosciences Inc.